Comment by willcipriano
Comment by willcipriano 4 days ago
I wouldn't count the Ozempic chickens before they roost. So far it looks like it's a costly lifelong injectable drug with a lot of reported uncomfortable side effects. That doesn't bode well for adherence at the population level.
Weekly injectable semaglutide is the first generation.
Tirzepatide is already more effective and better tolerated for most people, and there is also semaglutide as a daily oral pill available as Rybelsus. Further generations of obesity drugs are already in human trials, and are showing even greater effects relative to the side effects (e.g. retatrutide and combination therapy with cagrilintide).
Price is an issue, but with multiple pharma companies that have effective drugs, the prices have already come down quite a lot. My tirzepatide is running me less than £200/month now, and I'm saving at least that on groceries and eating out. Not even counting that it's effectively cured a few weight related medical conditions that were costing me more.